2. Academic Validation
  3. A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo

A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo

  • Commun Biol. 2023 Jun 1;6(1):592. doi: 10.1038/s42003-023-04955-3.
Fanlin Li # 1 2,  Wei Xu # 3,  Xiaoqing Zhang # 1 4,  Wanting Wang # 1 2,  Shan Su 3,  Ping Han 1 2,  Haiyong Wang 1 2,  Yanqin Xu 1 2,  Min Li 1 2,  Lilv Fan 1 2,  Huihui Zhang 1 2,  Qiang Dai 1 2,  Hao Lin 1 2,  Xinyue Qi 1 2,  Jie Liang 1 2,  Xin Wang 5,  Shibo Jiang 3,  Youhua Xie 6,  Lu Lu 7,  Xuanming Yang 8 9
Affiliations

Affiliations

  • 1 Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • 2 Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • 3 Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences and Biosafety Level 3 Laboratory, Fudan University, Shanghai, 200032, China.
  • 4 Department of Physiology, Naval Medical University, Shanghai, 200433, China.
  • 5 Shanghai Longyao Biotechnology Limited, Shanghai, 201203, China.
  • 6 Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences and Biosafety Level 3 Laboratory, Fudan University, Shanghai, 200032, China. [email protected].
  • 7 Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences and Biosafety Level 3 Laboratory, Fudan University, Shanghai, 200032, China. [email protected].
  • 8 Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China. [email protected].
  • 9 Joint International Research Laboratory of Metabolic & Developmental Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China. [email protected].
  • # Contributed equally.
PMID: 37264086 DOI: 10.1038/s42003-023-04955-3
Abstract

Neutralizing Antibodies exert a potent inhibitory effect on viral entry; however, they are less effective in therapeutic models than in prophylactic models, presumably because of their limited efficacy in eliminating virus-producing cells via Fc-mediated cytotoxicity. Herein, we present a SARS-CoV-2 spike-targeting bispecific T-cell engager (S-BiTE) strategy for controlling SARS-CoV-2 Infection. This approach blocks the entry of free virus into permissive cells by competing with membrane receptors and eliminates virus-infected cells via powerful T cell-mediated cytotoxicity. S-BiTE is effective against both the original and Delta variant of SARS-CoV2 with similar efficacy, suggesting its potential application against immune-escaping variants. In addition, in humanized mouse model with live SARS-COV-2 Infection, S-BiTE treated mice showed significantly less viral load than neutralization only treated group. The S-BiTE strategy may have broad applications in combating other coronavirus infections.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-D0938
    99.01%, Cell Proliferation Fluorescent Probe